EUVIMEDEUVIMED entdecken
Klinische Studie (Phase II)Multizentrische StudieOpen Access

Efficacy and Safety of Taletrectinib in Chinese Patients With ROS1+ Non–Small Cell Lung Cancer: The Phase II TRUST-I Study

Wei Li, Anwen Xiong, Nong Yang, Huijie Fan, Qitao Yu, Yanqiu Zhao, Yongsheng Wang, Xue Meng, Jingxun Wu, Ziping Wang, Yunpeng Liu, Xicheng Wang und 8 weitere

Journal of Clinical Oncology · 2024

DOI: 10.1200/jco.24.00731 ↗

Kurz gefasst

Klinische Studie (Phase II) in der Zeitschrift Journal of Clinical Oncology, 2024. Verfasst von Wei Li und 19 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medical Oncology, Shanghai Pulmonary Hospital and Thoracic Cancer Institute, Tongji University School of Medicine, Shanghai, China. Hauptthemen laut MEDLINE: Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Proto-Oncogene Proteins, Tyrosine Kinase Inhibitors. Die Arbeit wurde bisher 43-mal zitiert (Crossref) und nennt 24 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

PURPOSE Taletrectinib, a highly potent, CNS-active, ROS1 tyrosine kinase inhibitor (TKI), has demonstrated high and durable response rates, high intracranial objective response rate (ORR), prolonged progression-free survival (PFS), and activity against G2032R with a favorable safety profile. We report outcomes from the pivotal TRUST-I study (ClinicalTrials.gov identifier: NCT04395677 ) of taletrectinib for ROS1+ non–small cell lung cancer in China. METHODS TRUST-I evaluated TKI-naїve and crizotinib-pretreated patients. The primary end point was confirmed ORR (cORR) by independent review committee; key secondary end points included duration of response (DOR), PFS, and safety. RESULTS As of November 2023, 173 patients were enrolled (median age, 55 years; 58% female; 73% never smoked; TKI naїve: n = 106; crizotinib pretreated: n = 67). In TKI-naїve patients, cORR and intracranial cORR were 91% and 88%, respectively, and 52% and 73% in crizotinib-pretreated patients. In TKI-naїve patients, median DOR and median PFS were not reached (NR) with 22.1-month and 23.5-month follow-up, respectively. In crizotinib-pretreated patients, the median DOR was 10.6 months (95% CI, 6.3 months to NR; 8.4-month follow-up), and the median PFS was 7.6 months (95% CI, 5.5 to 12.0 months; 9.7-month follow-up). Eight of 12 patients (67%) with G2032R mutations responded. The most frequent treatment-emergent adverse events (TEAEs) were increased AST (76%), diarrhea (70%), and increased ALT (68%), most of which were grade 1-2. Incidences of neurologic TEAEs were low (dizziness: 23%; dysgeusia: 10%) and mostly grade 1. Discontinuations (5%) and dose reductions (19%) due to TEAEs were low. CONCLUSION Taletrectinib continues to show high and durable overall responses, prolonged PFS, robust activity against intracranial lesions and acquired resistance mutations including G2032R, and a favorable safety profile with a low incidence of neurologic TEAEs.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Carcinoma, Non-Small-Cell LungLung NeoplasmsProto-Oncogene ProteinsTyrosine Kinase InhibitorsAdultAgedFemaleHumansMaleMiddle AgedYoung AdultChinaCrizotinibEast Asian PeopleProgression-Free SurvivalProtein-Tyrosine KinasesImidazolesPyridazines

Substanzen

CrizotinibProto-Oncogene ProteinsTyrosine Kinase InhibitorsROS1 protein, humanProtein-Tyrosine KinasestaletrectinibImidazolesPyridazines

Autor:innen und Institutionen

  • Department of Medical Oncology, Shanghai Pulmonary Hospital and Thoracic Cancer Institute, Tongji University School of Medicine, Shanghai, China.
  • Hunan Cancer Hospital, The Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University, Changsha, China.
  • The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China.
  • Medical Oncology of Respiratory, Affiliated Tumor Hospital of Guangxi Medical University, Nanning, China.
  • Henan Cancer Hospital, Zhengzhou, China.
  • West China Hospital Sichuan University, Chengdu, China.

ORCID-Profile: Christine M Lovly, Caicun Zhou

Zitieren

APA

Li, W., Xiong, A., Yang, N., Fan, H., Yu, Q., Zhao, Y., Wang, Y., Meng, X., Wu, J., Wang, Z., Liu, Y., Wang, X., Qin, X., Lu, K., Zhuang, W., Ren, Y., Zhang, X., Yan, B., Lovly, C. M., & Zhou, C. (2024). Efficacy and Safety of Taletrectinib in Chinese Patients With ROS1+ Non–Small Cell Lung Cancer: The Phase II TRUST-I Study. Journal of Clinical Oncology. https://doi.org/10.1200/jco.24.00731

Vancouver

Li W, Xiong A, Yang N, Fan H, Yu Q, Zhao Y, et al. Efficacy and Safety of Taletrectinib in Chinese Patients With ROS1+ Non–Small Cell Lung Cancer: The Phase II TRUST-I Study. Journal of Clinical Oncology. 2024. doi:10.1200/jco.24.00731

BibTeX
@article{Li2024,
  author = {Li, Wei and Xiong, Anwen and Yang, Nong and Fan, Huijie and Yu, Qitao and Zhao, Yanqiu and Wang, Yongsheng and Meng, Xue and Wu, Jingxun and Wang, Ziping and Liu, Yunpeng and Wang, Xicheng and Qin, Xintian and Lu, Kaihua and Zhuang, Wu and Ren, Yizhong and Zhang, Xianyu and Yan, Bing and Lovly, Christine M and Zhou, Caicun},
  title = {Efficacy and Safety of Taletrectinib in Chinese Patients With ROS1+ Non–Small Cell Lung Cancer: The Phase II TRUST-I Study},
  journal = {Journal of Clinical Oncology},
  year = {2024},
  doi = {10.1200/jco.24.00731}
}
Kostenlos starten →